- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 08.01. | Flagship-founded Tessera plans to lay off 90 employees in March | ||
| 08.01. | J&J, Google venture arms line up to back protein degradation biotech EpiBiologics' $107M series B | ||
| 08.01. | Foresee offloads MMP-12 inhibitors in $584M deal, focuses on Camcevi's potential | ||
| 08.01. | Lilly buys inflammation biotech Venytx for $1.2B in wake of Parkinson's, CV readouts | ||
| 08.01. | Immuneering touts 64% 1-year survival, keeping wheels turning in race with Revolution | ||
| 07.01. | Lilly links up with InduPro in next-gen cancer treatment deal worth up to $950M | ||
| 07.01. | Pulmocide calls curtains on phase 3 antifungal trial over low response, higher mortality rate | ||
| 07.01. | Amgen dances with Disco in $618M cancer target pact | ||
| 07.01. | Rakuten lights path to 2028 FDA filing with fresh $100M raise | ||
| 07.01. | Soley secures $200M series C to push AML cell stress drug into clinic | ||
| 07.01. | Basilea pens collab with US biotech to develop new antifungal | ||
| 07.01. | GSK's 'functional cure' for hep B proves worth in phase 3 trials setting up approval push | ||
| 07.01. | Hutchmed heats up autoimmune race with phase 3 win, teeing up China filing | ||
| 06.01. | Boehringer continues kidney disease dealmaking run with $120M Variant Bio pact | ||
| 06.01. | Bright Minds shines with phase 2 win for anti-seizure serotonin receptor activator | ||
| 06.01. | Amgen stitches new acquisition worth up to $840M for UK biotech and its cancer programs | ||
| 06.01. | In Structure licensing deal, Roche commits $100M to shore up GLP-1 position | ||
| 06.01. | Arrowhead takes aim at obesity market with early data on dual gene silencing assets | ||
| 06.01. | Lilly returns to Nimbus with $1.3B deal to create new oral obesity drug | ||
| 06.01. | Alumis beams as pivotal data on Sotyktu rival drive stock surge | ||
| 06.01. | Instil's stock sinks after it clears out pipeline, hands 2 drugs back to ImmuneOnco | ||
| 06.01. | UK biotech eyes $1B deal to enable eye gene therapy to be delivered in doctors' offices | ||
| 05.01. | MetaVia weighs in with 9% loss as dual agonist enters the obesity ring | ||
| 05.01. | Zenas' stock sinks in wake of autoimmune phase 3 data despite primary endpoint hit | ||
| 05.01. | Aktis Oncology aims for $209M windfall from 1st biotech IPO of 2026 |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.